Aurinia Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the Securities and Exchange Commission on October 30, 2026, reporting net income of $31.7 million for the third quarter and $103.5 million for the nine months ended September 30, 2026.

Key Highlights

  • Third-quarter net product sales were $79.418 million, compared with $70.627 million in the same period of 2025, according to the filing.
  • Nine-month total revenue reached $244.624 million, up from $205.941 million for the nine months ended September 30, 2025.
  • Nine-month net income was $103.472 million, compared with $76.408 million for the prior-year period, the filing disclosed.
  • Diluted earnings per share were $0.23 for Q3 2026 and $0.76 for the nine months ended September 30, 2026.
  • Total assets stood at $825.704 million as of September 30, 2026, up from $751.587 million at December 31, 2025.
  • Share repurchases totaling 4,974 thousand shares were made under the Share Repurchase Plan during the nine months ended September 30, 2026, reducing the share count from 132,323 thousand at December 31, 2025.
  • Common shares outstanding as of October 29, 2026 were 133,998,660, the registrant reported.

Aurinia's Revenue Growth and Profitability in the Nine Months Ended September 30, 2026

According to the filing, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported total revenue of $83.699 million for the three months ended September 30, 2026, consisting of $79.418 million in net product sales and $4.281 million in license, collaboration and royalty revenue. For the nine-month period, total revenue was $244.624 million, with net product sales of $232.393 million and license, collaboration and royalty revenue of $12.231 million. Both figures represent increases over the comparable 2025 periods, when three-month total revenue was $73.468 million and nine-month total revenue was $205.941 million.

The filing reported income from operations of $35.363 million for Q3 2026 and $123.126 million for the nine months ended September 30, 2026, compared with $29.745 million and $71.675 million, respectively, in the prior-year periods. Research and development expenses increased to $16.613 million in Q3 2026 from $8.435 million in Q3 2025, and to $37.133 million for the nine months from $21.610 million in the same period of 2025. Selling, general and administrative expenses were $24.684 million for the quarter and $70.221 million for the nine-month period, the company disclosed.

On the balance sheet, the filing showed total shareholders' equity of $657.519 million at September 30, 2026, compared with $581.331 million at December 31, 2025. Short-term investments grew to $440.735 million from $317.784 million over that period. Cash, cash equivalents and restricted cash were $46.145 million at September 30, 2026, down from $80.213 million at December 31, 2025. The accumulated deficit narrowed to $545.896 million from $649.368 million at December 31, 2025, reflecting the cumulative net income recognized during the period, according to the filing.

What Was Disclosed

Aurinia Pharmaceuticals filed a Form 10-Q covering the quarter and nine months ended September 30, 2026, reporting net income of $31.703 million for Q3 and $103.472 million for the nine-month period, along with balance sheet, equity, and operational data for the period.